Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects.

American journal of therapeutics

Volumn 11, Issue 3, 2004, Pages 175-189

  Shah, Bharti ^a   Rohatagi, Shashank ^a   Natarajan, Chandrasekhar ^a   Kirkesseli, Stephane ^a   Baybutt, Robert ^a   Jensen, Bradford K ^a  

^a Aventis Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ANTILIPEMIC AGENT; FATTY ACID; TRIACYLGLYCEROL;

ADULT; ANIMAL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; HALF LIFE TIME; HUMAN; MALE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; RECEPTOR, ADENOSINE A1; SPECIES SPECIFICITY; TRIGLYCERIDES;

EID: 3843050400     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200405000-00005     Document Type: Article

References (0)